US8143241 — DNA damage repair inhibitors for treatment of cancer
Method of Use · Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2027-08-12 · 1y remaining
What this patent protects
This patent provides methods and means for treating cancers that are deficient in a specific type of DNA repair using inhibitors that target the base excision repair pathway.
USPTO Abstract
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Drugs covered by this patent
- rucaparib-camsylate (RUCAPARIB CAMSYLATE)
- Lynparza (olaparib) · AstraZeneca
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2830 |
— | |
U-2830 |
— | |
U-2655 |
— | |
U-2273 |
— | rucaparib-camsylate |
U-2655 |
— | |
U-2655 |
— | |
U-2012 |
— | rucaparib-camsylate |
U-2012 |
— | rucaparib-camsylate |
U-2482 |
— | Lynparza |
U-2480 |
— | Lynparza |
U-1634 |
— | Lynparza |
U-2655 |
— |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.